TAK-715是一种 p38 MAPK 抑制剂,专门针对 p38α,IC50 为 7.1 nM,对 p38β 的选择性是 p38α 的 28 倍,对 p38γ/δ、JNK1、ERK1、IKKβ、MEKK1 或 TAK1 无抑制作用。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | p38 MAPK ↓ ↑ | p38α ↓ ↑ | p38β ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMS-582949 |
+++
p38 MAPK, IC50: 13 nM |
98% | |||||||||||||||||
| Adezmapimod | 99%+ | ||||||||||||||||||
| Pexmetinib | ✔ | Tie-2 | 99%+ | ||||||||||||||||
| Skepinone-L |
++++
p38α, IC50: 5 nM |
98% | |||||||||||||||||
| Doramapimod |
++++
p38α, IC50: 38 nM p38α, Kd: 0.1 nM |
99%+ | |||||||||||||||||
| VX-702 | 99%+ | ||||||||||||||||||
| Ralimetinib dimesylate |
++++
p38α, IC50: 7 nM |
98% | |||||||||||||||||
| SB 202190 |
++
p38α, IC50: 50 nM |
++
p38β, IC50: 100 nM |
99%+ | ||||||||||||||||
| Losmapimod |
++++
p38α, pKi: 8.1 |
+++
p38β, pKi: 7.6 |
99%+ | ||||||||||||||||
| Neflamapimod |
+++
p38α, IC50: 10 nM |
+
p38β, IC50: 220 nM |
99%+ | ||||||||||||||||
| PH-797804 |
++
p38α, IC50: 26 nM |
+
p38β, IC50: 102 nM |
99% | ||||||||||||||||
| TAK-715 |
++++
p38α, IC50: 7.1 nM |
+
p38β, IC50: 0.20 μM |
99%+ | ||||||||||||||||
| SB 239063 |
++
p38α, IC50: 44 nM |
++
p38β, IC50: 44 nM |
99%+ | ||||||||||||||||
| Pamapimod |
+++
p38α, IC50: 0.014 μM |
+
p38β, IC50: 0.48 μM |
98%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | CK1 ↓ ↑ | CK2 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PF-670462 2HCl |
++++
CK1δ, IC50: 13 nM CK1ε, IC50: 90 nM |
99%+ | |||||||||||||||||
| D4476 |
++
CK1δ, IC50: 300 nM CK1 from Schizosaccharomyces pombe, IC50: 200 nM |
99% | |||||||||||||||||
| SR-3029 |
+++
CK1δ, IC50: 44 nM CK1ε, IC50: 260 nM |
99%+ | |||||||||||||||||
| IWP-2 |
+++
M82FCK1δ, IC50: 40 nM |
Wnt | 99% | ||||||||||||||||
| LY364947 |
++
CK1δ, IC50: 0.22 μM |
98% | |||||||||||||||||
| TA-01 |
++++
CK1δ, IC50: 6.8 nM CK1ε, IC50: 6.4 nM |
p38 MAPK | 99%+ | ||||||||||||||||
| IC261 |
+
CK1, IC50: 16 μM |
98% | |||||||||||||||||
| PF-4800567 |
+++
casein kinase 1 delta, IC50: 711 nM casein kinase 1 epsilon, IC50: 32 nM |
99%+ | |||||||||||||||||
| CK1-IN-1 |
++++
CK1δ, IC50: 15 nM CK1ε, IC50: 16 nM |
99% | |||||||||||||||||
| Longdaysin |
+
CKIδ, IC50: 8.8 μM CKIα, IC50: 5.6 μM |
99%+ | |||||||||||||||||
| Silmitasertib |
++++
CK2, IC50: 1 nM |
99%+ | |||||||||||||||||
| Ellagic acid (hydrate) |
+++
CK2, IC50: 0.04 μM |
PKA | 95+% | ||||||||||||||||
| DMAT |
+++
CK2, Ki: ~40 nM |
99% | |||||||||||||||||
| Hematein |
++
CK2, IC50: 0.55 μM |
40% | |||||||||||||||||
| Silmitasertib sodium salt |
++++
CK2α, IC50: 1 nM CK2α', IC50: 1 nM |
99%+ | |||||||||||||||||
| LY294002 |
+++
CK2, IC50: 98 nM |
99%+ | |||||||||||||||||
| A-3 HCl |
+
CK1, Ki: 80 μM |
++
CK2, Ki: 5.1 μM |
PKA,MLCK,PKC | 98+% | |||||||||||||||
| TBB |
+
CK1, Ki: 47 μM |
++
CK2, Ki: 0.4 μM |
98% | ||||||||||||||||
| TTP 22 |
++
CK2, IC50: 100 nM |
98%+ | |||||||||||||||||
| DRB | ✔ | 99%+ | |||||||||||||||||
| BioE-1115 |
+
CK2α, IC50: 10 μM |
99%+ | |||||||||||||||||
| (E/Z)-GO289 |
++++
CK2, IC50: 7 nM |
99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | The stress-activated protein kinase (SAPK) p38 isoforms are mitogen-activated protein kinase (MAPK) family members. MAPKs act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The well reported isoforms of p38 MAPKs include p38α, p38β and others. TAK-715 is a p38 MAPK inhibitor, with selectivity for p38α. The inhibitory IC50 of TAK-715 against p38α was 7.1nM while the data against p38β was 200nM. TAK-715 was not active against p38γ, p38δ, or other kinases. TAK-715 inhibited LPS-stimulated release of TNFα from THP-1 cells with an IC50 of 48 nM[3]. At the concentration of 10μM, TAK-715 inhibited Wnt-3a-induced hDvl2 phosphorylation and the hDvl2 shift in U2OS-EFC cells[4]. Orally administrated at the dose of 10mg/kg, TAK-715 resulted in 87.6% inhibition of LPS-induced TNFα production in mice. In an adjuvant-induced arthritis model in rats, TAK-715 dose dependently inhibited paw swelling when given daily for 14 days at 3mg/kg, 10mg/kg or 30mg/kg[3]. |
| 作用机制 | TAK-715 target p38α in an ATP-competitive manner[4]. |
| Concentration | Treated Time | Description | References | |
| Human adipose stem cells (hASCs) | 10 µM | 12 days | TAK-715 significantly suppressed lipid accumulation during the differentiation of hASCs and downregulated the phosphorylation of p38 MAPK. | Life (Basel). 2023 Feb 1;13(2):412. |
| Rat NPCs | 0, 0.05, 0.1, 0.25, 0.5, 1.0, 5, 10 µM | 24 and 48 hours | To evaluate the cytotoxicity of TAK-715 on NPCs, the results showed that TAK-715 was not toxic to NPCs at concentrations below 1.0 μM and could slightly decrease the cellular activity of NPCs | Arthritis Res Ther. 2023 Mar 21;25(1):45. |
| 3T3-L1 preadipocytes | 10 µM | 8 days | TAK-715 significantly suppressed lipid accumulation and intracellular triglyceride content during the differentiation of 3T3-L1 preadipocytes, and downregulated the expression and phosphorylation of C/EBP-α, PPAR-γ, STAT-3, FAS, perilipin A, p38 MAPK, and its downstream effector ATF-2. | Life (Basel). 2023 Feb 1;13(2):412. |
| Administration | Dosage | Frequency | Description | References | ||
| SD rats | Puncture-induced intervertebral disc degeneration model | Intradiscal injection | 5 μl (1 μM) | Single injection | To evaluate the ameliorative effect of TAK-715 on intervertebral disc degeneration in vivo, the results showed that TAK-715 delayed disc degeneration by inhibiting NPC apoptosis and ECM degradation | Arthritis Res Ther. 2023 Mar 21;25(1):45. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.50mL 0.50mL 0.25mL |
12.52mL 2.50mL 1.25mL |
25.03mL 5.01mL 2.50mL |
|
| CAS号 | 303162-79-0 |
| 分子式 | C24H21N3OS |
| 分子量 | 399.51 |
| SMILES Code | O=C(NC1=NC=CC(C2=C(C3=CC=CC(C)=C3)N=C(CC)S2)=C1)C4=CC=CC=C4 |
| MDL No. | MFCD17012805 |
| 别名 | |
| 运输 | 蓝冰 |
| InChI Key | HEKAIDKUDLCBRU-UHFFFAOYSA-N |
| Pubchem ID | 9952773 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(262.82 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1